Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics Inc. Hosts First Analyst Day Focused on Previewing its Corporate Vision and Commercial Strategy
Company Also Announces Four New Patents Granted for its Novel Transdermal Contraceptive Dosing Regimens...
Toggle Summary Agile Therapeutics Joins Russell Microcap® Index
PRINCETON, N.J. , June 30, 2014 /PRNewswire/ -- Agile Therapeutics, Inc. , (NASDAQ: AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced it has been added to the Russell Microcap Index....
Toggle Summary Agile Therapeutics Launches I’m So Done Campaign to Inspire Women to Take an Active Role in Choosing their Birth Control
Visit  BirthControlDoneMyWay.com to learn more about some of the many available contraceptive options I’m So Done is a national unbranded campaign intended to enhance the birth control conversation for women Encourage education on contraceptive care options Facilitate an honest discussion between...
Toggle Summary Agile Therapeutics Named Finalist for PACT 2012
Toggle Summary Agile Therapeutics Partners with Carli Lloyd, U.S. Women’s Soccer Star and Four-Time Olympian, to Bring Awareness to Women’s Health Topics
Partnership to focus on empowering women to take ownership of their health and healthcare options PRINCETON, N.J., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX ), a women's healthcare company, announced today a partnership with U.S. Women’s Soccer legend, Carli Lloyd ....
Toggle Summary Agile Therapeutics Partners with Telehealth Service, Pandia Health, to Increase Women’s Access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system
Pandia Health is a doctor founded and led telehealth company, offering online prescriptions and free delivery designed to make it easier for women to access birth control options that meet their needs Partnership represents first telehealth alliance for Agile’s Twirla ® birth control patch...
Toggle Summary Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla® at the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo 2017
Data Suggests Twirla May Decrease Mean Length of Bleeding and Spotting Episodes...
Toggle Summary Agile Therapeutics Presents Additional Twirla® Phase 3 SECURE Study Results at NAFFP 2017
Detailed Bleeding Profile Data Provide Helpful Information for Patient Counseling PRINCETON, N.J., Oct. 16, 2017 – Agile Therapeutics, Inc., (NASDAQ: AGRX), a women’s healthcare company, today announced the presentation of additional results from the Phase 3 SECURE trial of its investigational...
Toggle Summary Agile Therapeutics President and CEO appointed to Board of BioNJ
Toggle Summary Agile Therapeutics President and Chief Executive Officer Al Altomari is an Ernst & Young Entrepreneur Of The Year® 2012 finalist in New Jersey
Shadow